Evidence map›Paper›PMID 41736399›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2026

Anti-CD19-engineered exosomes enable B cell-targeted anti-BAFF mRNA delivery to alleviate lupus progression.

Linda Zeng, Jingxian Shu, Shuping Zhong, Xin Dong, Yongjian Wu, Xi Huang

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Linda ZengCenter for Infection and Immunity and Guangdong Provincial Engineering Research Center of Molecular Imaging, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong Province 519000, China.
Jingxian ShuCenter for Infection and Immunity and Guangdong Provincial Engineering Research Center of Molecular Imaging, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong Province 519000, China; Department of Pharmacy, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong Province 519000, China.
Shuping ZhongRheumatology and Immunology Department, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong Province 519000, China.
Xin DongCenter for Infection and Immunity and Guangdong Provincial Engineering Research Center of Molecular Imaging, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong Province 519000, China.
Yongjian WuCenter for Infection and Immunity and Guangdong Provincial Engineering Research Center of Molecular Imaging, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong Province 519000, China. Electronic address: wuyj228@mail.sysu.edu.cn.
Xi HuangCenter for Infection and Immunity and Guangdong Provincial Engineering Research Center of Molecular Imaging, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong Province 519000, China. Electronic address: huangxi6@mail.sysu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by abnormal activation of B cells. Excessive B cell activating factor (BAFF) of the tumor necrosis factor family plays an essential role in B cell hyperactivation. Blocking the binding of excessive BAFF to its receptors is becoming a promising approach for SLE treatment. Here, we constructed genetically engineered exosomes derived from HEK293 cells that were functionalized with anti-CD19 (a B cell-specific surface marker) and loaded with anti-BAFF mRNA (CD19@Anti-BAFF

Indexed as

Antigens, CD19B-Cell Activating FactorB-LymphocytesExosomesLupus Erythematosus, SystemicRNA, MessengerAnimalsDisease Models, AnimalDisease ProgressionFemaleHEK293 CellsHumansMiceAntigens, CD19B-Cell Activating FactorRNA, MessengerBAFFB cell activating factorexosomesSLEsystemic lupus erythematosustargeted delivery

Identifiers

PMID41736399
PMCPMC13238940

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.